Skip to main content
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. logo

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. — Investor Relations & Filings

Ticker · 688796 LEI · 549300F4L1TRSHBRCU87 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 64 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688796

About BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

https://biocytogen.com/

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology organization focused on the discovery and development of novel antibody-based therapeutics. The company utilizes its proprietary RenMice platform, comprising RenMab, RenLite, and RenNano, to produce fully human monoclonal, bispecific, and single-domain antibodies. Its integrated business model encompasses gene-edited animal model development, large-scale antibody discovery via the Project Integrum initiative, and specialized preclinical pharmacology services. By leveraging advanced CRISPR/Cas9-based gene editing and high-throughput screening, the company facilitates the identification and validation of therapeutic targets. Biocytogen provides comprehensive R&D solutions to global pharmaceutical and biotechnology partners, focusing on therapeutic areas such as oncology, inflammation, and metabolic diseases.

Recent filings

Filing Released Lang Actions
北京市中伦律师事务所关于百奥赛图（北京）医药科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 82% confidence The document is a legal opinion letter (“法律意见书”) provided by outside counsel on the legality of the 2025 annual shareholders meeting, including convening procedures, attendee qualifications, voting procedures, and voting results. It is not an annual report, earnings release, or investor presentation, nor merely a vote results announcement. It functions as an external legal attestation/compliance document rather than substantive financial statements or meeting materials. Under the filing definitions and the CERTIFICATION RULE, such attestations and compliance letters fall into the “Regulatory Filings” (RNS) category as a fallback for compliance documents and certifications.
2026-05-21 Chinese
百奥赛图（北京）医药科技股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement titled “2025年年度股东会决议公告” detailing the date, attendance, and full voting results for each resolution proposed at the 2025 Annual General Meeting. It lists vote counts, percentages, and confirms the approval of each motion. This corresponds to a Declaration of Voting Results & Voting Rights Announcement, not the meeting materials themselves or the full annual report.
2026-05-21 Chinese
百奥赛图（北京）医药科技股份有限公司关于召开2025年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 75% confidence The document is an announcement (公告) of a 2025 annual and 2026 Q1 performance explanation meeting (an earnings call invite), including time, place, participants, and how to join. It contains no actual financial statements or numerical results, nor is it a full transcript or presentation deck. There is no new earnings release data nor an attached report. This is a regulatory announcement that doesn’t fit any other specific category, so it falls under the general Regulatory Filings (RNS) category.
2026-05-19 Chinese
百奥赛图（北京）医药科技股份有限公司2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled “2025年年度股东会会议资料” and contains the full set of materials for the 2025 Annual Shareholders’ Meeting – including meeting notices, agendas, proposals (board work report, audit appointment, related-party transactions, dividend proposal, director compensation, capital changes, financing guarantee, etc.). This matches the definition of AGM Information, i.e., materials shared at the Annual General Meeting.
2026-05-15 Chinese
毕马威华振会计师事务所（特殊普通合伙）关于百奥赛图（北京）医药科技股份有限公司2025年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 87% confidence The document is titled as a "专项说明" (special explanation) of 2025 non-operating fund occupancy and related-party transactions, prepared and attested by KPMG Huazhen LLP for inclusion in the company’s 2025 annual report. It contains auditor’s attestation language and detailed summary tables rather than a full annual or quarterly financial report, indicating a standalone audit information piece. This matches the definition of an Audit Report / Information (AR). FY 2025
2026-03-26 Chinese
百奥赛图（北京）医药科技股份有限公司2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2025 by 百奥赛图（北京）医药科技股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025, including financial and non-financial internal control defects, audit opinions, and corrective actions. The content is focused on internal control evaluation rather than a full annual report or audit report. The document length is 4169 characters, which is relatively short but contains substantive evaluation content rather than just an announcement. This type of report fits best under the category of Audit Report / Information (AR), as it is a standalone report on internal control evaluation and audit opinions, not a full annual report or other filing types. FY 2025
2026-03-26 Chinese

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.